Please select the option that best describes you:

How would you treat a young patient with good performance status who has de novo metastatic HR+ Her2+ inflammatory breast cancer with asymptomatic leptomeningeal and CNS parenchymal disease?  



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Providence Western Washington Onc, Inc
Both Neratinib and Tucatinib Have recently good s...
Sign in or Register to read more